Neotropix Initiates Phase II Lung Cancer Trial

Neotropix began enrolling patients in a Phase II trial to assess the efficacy of the novel oncolytic virus, NTX-010, in patients with extensive stage small cell lung cancer (SCLC). NTX-010 has been shown to be highly selective for certain neuroendocrine tumor types including SCLC.

The current study is designed to determine activity of a single dose of NTX-010 when used immediately after completion of standard first line therapy for SCLC as NTX-010 replicates within the tumor generating more drug as it destroys the cancer cells.

Anthony Williams, M.D., chief medical officer at Neotropix, commented, “Oncolytic viruses are an innovative approach to cancer treatment in which the very specific destruction of cells by a virus is directed against a patient’s tumor cells, offering the ability to kill the cancer without affecting normal cells, resulting in significantly less side effects. Neotropix’s NTX-010 is highly unique among this class of agents in that it is an unengineered ‘natural product’ with innate anti-cancer activities.”